Explore more price target data and ratings for Alnylam Pharmaceuticals, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Alnylam Pharmaceuticals, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Syst…
Q2 net product revenues surged 74% year-over-year to $1.2 billion, led by AMVUTTRA’s strong first-line growth and robust U.S. and international demand. 2026 revenue guidance was revised down by $200 million due to normalized second-line demand, but long-term growth targets remain intact, supported…
Q2 net product revenues surged 74% year-over-year to $1.2 billion, led by AMVUTTRA's strong first-line growth and robust U.S. demand. 2026 revenue guidance was lowered by $200 million at midpoint due to normalized second-line demand, but long-term growth targets remain supported by a large untreate…
Alnylam reported second-quarter 2026 total revenues of $1.291 billion and GAAP net income of $164.5 million, driven by strong product sales. Total net product revenues were $1.172 billion, with AMVUTTRA accounting for $1.012 billion of TTR net product revenues. The company updated full-year 2026 TT…
Analysts kept Buy on Alnylam Pharmaceuticals (NASDAQ:ALNY) even as Bank of America and Truist cut 12‑month targets to $410 while HC Wainwright raised its target to $485; the company will report Q2 2026 results July 30 before the U.S. open with a conference call at 8:30 a.m. ET.Previous Week Recap…
Explore more price target data and ratings for Alnylam Pharmaceuticals, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Alnylam Pharmaceuticals, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Syst…
Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo and Amvuttra — that together generated $1.04 billion in net product revenues, representing a 121% year-over-year increase in the first quarter of 2026. The company also recognizes collaboration revenues…
